KRAS is the most frequently mutated oncogene, and KRAS mutations are well-validated drivers of oncogenesis 1. As such, significant effort has been focused on developing direct inhibitors of KRAS and ...
Aminoacyl-tRNA synthetases (AARSs), a family of essential protein synthesis enzymes, are attractive targets for drug development. Although several different types of AARS inhibitors have been ...